Trial Profile
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Sep 2022
Price :
$35
*
At a glance
- Drugs Baricitinib (Primary)
- Indications Atopic dermatitis
- Focus Registrational; Therapeutic Use
- Acronyms BREEZE-AD5
- Sponsors Eli Lilly and Company
- 01 Jul 2022 Results of post hoc analysis assessing the rapid changes in skin pain severity with baricitinib, and its impact on patient quality of life (QoL) in adults with moderate-to-severe atopic dermatitis published in the Journal of Cutaneous Medicine and Surgery.
- 01 Jun 2022 Results published in the Journal of Dermatological Treatment
- 01 May 2022 Results of subanalysis evaluating how quickly baricitinib 1-mg and 2-mg reduced itch and associated sleep disturbance during the first 7 days after treatment initiation, published in the Journal of Cutaneous Medicine and Surgery